| 產品名稱 |
Proteus mirabilis Hauser |
| 商品貨號 |
B214692 |
| Strain Designations |
Pm 631 |
| Application |
Produces beta-lactamase TEM-89 |
| Isolation |
Blood - human, blood culture from paraplegic and diabetic patient, University Hospital, Dijon, France, April 21, 2000 |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format |
freeze-dried |
| Storage Conditions |
Frozen: -80°C or colder
Freeze-Dried: 2°C to 8°C
Live Culture: See Propagation Section |
| Preceptrol® |
no |
| Type Strain |
no |
| Medium |
ATCC® Medium 18: Trypticase Soy Agar/Broth
|
| Growth Conditions |
Temperature: 37°C Atmosphere: Aerobic |
| Name of Depositor |
C Neuwirth |
| Special Collection |
NCRR Contract |
| Year of Origin |
2000 |
| References |
Neuwirth C, et al. TEM-89 beta-lactamase produced by a Proteus mirabilis clinical isolate: new complex mutant (CMT 3) with mutations in both TEM-59 (IRT-17) and TEM-3. Antimicrob. Agents Chemother. 45: 3591-3594, 2001. PubMed: 11709345
|
| Cross References |
Nucleotide (GenBank) :
AY039040
Proteus mirabilis TEM-89 beta-lactamase (TEM-89) gene, partial cds.
|
